Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment  by Sørensen, Jens Benn et al.
ORIGINAL ARTICLE
Pemetrexed as Second-Line Treatment in Malignant Pleural
Mesothelioma after Platinum-Based First-Line Treatment
Jens Benn Sørensen, MD, DMSc, MPA,* Stein Sundstrøm, MD, DMSc,† Katharina Perell, MD,*
and Anne-Kathrine Thielsen, MD*
Introduction: Pemetrexed is active as first-line treatment of malig-
nant pleural mesothelioma. The objective was to evaluate its activity
as second-line treatment.
Methods: Patients had disease progression of malignant pleural
mesothelioma after previous platinum-based regimens without pem-
etrexed. Treatment was pemetrexed alone or pemetrexed combined
with carboplatin. Pemetrexed dosing was 500 mg/m2 and carbopla-
tin was AUC (area under the curve) 5 once every 3 weeks.
Results: Thirty-nine patients were included: 28 Danish patients
received pemetrexed (three patients received pemetrexed as third-
line treatment), whereas 11 Norwegian patients received pemetrexed
plus carboplatin. Most patients were men (90%), had epithelial
subtype (85%), and International Mesothelioma Interest Group
stages III to IV (77%). Median age was 62 years (range, 30–77). The
median number of treatment courses was six (range, 1–23). Com-
mon Toxicity Criteria grade 3 to 4 toxicity occurred only with
respect to leukocytopenia (pemetrexed: 14% of patients; pemetrexed
plus carboplatin: 9%) and thrombocytopenia (pemetrexed: 7%; pem-
etrexed plus carboplatin: 18%). One patient receiving pemetrexed
died of sepsis. Partial response rates were 21% and 18%, the median
time to progression was 21 weeks (range, 4–92) and 32 weeks
(range, 4–128), and the median survival was 42 weeks (range,
4–99) and 39 weeks (range, 10–128) with pemetrexed and pem-
etrexed plus carboplatin, respectively.
Conclusions: Pemetrexed was generally well tolerated with note-
worthy activity in malignant pleural mesothelioma after previous
platinum-based treatment and may be considered for second-line
treatment.
Key Words: Alimta, Pemetrexed, Pleural mesothelioma, Second-
line treatment.
(J Thorac Oncol. 2007;2: 147–152)
Malignant pleural mesothelioma (MPM) is a lethal lesionin most cases, and only a few patients are eligible for
curative surgery.1 The median survival is 12 months, but only
12% of patients with poor prognostic factors survive 1 year.2
Chemotherapy for MPM is challenging, although several
cytotoxic agents have been tested and the rates of objective
tumor response have ranged from 10% to 30% with mono-
therapy.3 Cisplatin and carboplatin are both active and thus
included in the most used combination regimens for MPM.4
Pemetrexed is a multitargeted antifolate with a 14% response
rate as a single agent in chemotherapy-naive MPM patients.5
Recently, a large randomized trial demonstrated that combi-
nation chemotherapy with pemetrexed and cisplatin signifi-
cantly increased both survival time (from 9.3 to 12.1 months)
and time to progression (from 3.9 to 5.7 months) compared
with cisplatin monotherapy.6 Thus, the combination of pem-
etrexed and cisplatin is a reference combination for first-line
treatment of MPM.
Patients with progression after first-line treatment may
often be in good health and commonly inquire about second-
line treatment. Only few data are available to guide the
oncologist in selecting such treatment because the vast ma-
jority of previously reported trials in MPM included solely
previously untreated patients. Thus, it was the aim of this
study to evaluate pemetrexed as second-line chemotherapy or
beyond in MPM patients not previously exposed to this agent.
MATERIALS AND METHODS
Patients
Eligibility criteria included histologically proven
MPM, progression after platinum-based combination chemo-
therapy, measurable disease, Eastern Cooperative Oncology
Group performance status of 0 to 2, estimated survival ex-
pectancy of 3 months, age 18 years or older, and written
informed consent.
Adequate organ functions were required, defined as
white blood cell count 3000/l, platelet count 100,000/
l, hemoglobin 9.0 g/dl, bilirubin 1.25 times the upper
limit of normal, aspartate aminotransferase and alanine ami-
notransferase 2.5 times the upper limit of normal, and
creatinine 2.0 mg/dl.
Exclusion criteria included previous exposure to pem-
etrexed, significant medical or psychiatric comorbidity, cen-
tral nervous metastases, pregnant or lactating women, and
history of cancers in the previous 5 years or breast cancer ever.
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All women of reproductive age were to use safe contraception.
The standards of Helsinki Declaration were fulfilled.
Treatment
Danish patients received pemetrexed monochemotherapy
500 mg/m2 as a 10-minute infusion every 3 weeks. Norwegian
patients received same dose of pemetrexed with carboplatin area
under the curve (AUC) 5 (pemetrexed plus carboplatin), both
administered day 1 every 3 weeks. The difference in treatment
between Danish and Norwegian patients was solely a difference
in general treatment strategy due to which Norwegian patients
were reinduced with carboplatin after previous exposure to this
agent, whereas this was not the strategy in Denmark. The two
data sets were not part of a common study but were combined
after treatment of the two cohorts.
Folic acid 400 g/day orally and vitamin B12 1000 mg
administered intramuscularly every 9 weeks were used in
both regimens, beginning 1 to 3 weeks before study start.
Prednisolone 50 mg was administered twice daily on the day
before, on the day of, and on the day after pemetrexed to
reduce the risk of severe skin rash. Standard antiemetic
prophylaxis with 5-hydroxytryptamine-3 antagonists and
metoclopramide was administered before chemotherapy.
Before start of any cycle, the total leukocyte count had to
be 3.0 x 109/liter, absolute neutrophil count 1.5  109/liter,
and platelet count 100  109/liter. On recovery, patients with
a nadir total leukocyte count 1.0  109/liter, absolute neutro-
phil count 0.5  109/liter, or platelet count 25  109/liter
received 75% of the previous pemetrexed dose. In the event of
grade 3 or 4 nonhematologic toxicities, treatment was delayed
until there was resolution to grade 1 or less before proceeding.
Therapy was then resumed at 75% of the previous dose level, if
deemed appropriate by the treating physician. Dose delays up to
42 days were permitted for recovery from study drug toxicity.
Dose escalations were not allowed.
TABLE 1. Characteristics for 39 Malignant Pleural Mesothelioma Patients Previously Treated with
Platinum-Based Chemotherapy and Receiving Second- or Third-Line Treatment with Pemetrexed
No. of Patients (%)
Pemetrexed
(n  28)
Pemetrexed  Carboplatin
(n  11)
Total
(n  39)
Gender, no. (%)
Male 26 (93) 9 (82) 35 (90)
Female 2 (7) 2 (18) 4 (10)
Stage, no. (%)
Ib 1 (4) 0 1 (3)
II 4 (14) 4 (36) 8 (20)
III 12 (43) 6 (55) 18 (46)
IV 11 (39) 1 (9) 12 (31)
Performance status, no. (%)
0 8 (29) 1 (9) 9 (28
1 17 (61) 9 (82) 26 (67)
2 3 (11) 1 (9) 4 (10)
Histology, no. (%)
Epithelial 22 (79) 11 (100) 33 (85)
Sarcomatous 1 (4) 0 1 (2)
Biphasic 5 (18) 0 5 (13)
Age, yr
Median (range) 62 (30–73) 62 (43–77) 62 (30–77)
Lead time from diagnosis to study start (d)
Median (range) 283 (86–956) 389 (174–778) 308 (86–956)
1st line treatment, no. (%)
Vinorelbine  cisplatin 21 (75) 0 21 (54)
Vinorelbine  carboplatin 2 (7) 0 2 (5)
Gemcitabine  carboplatin 5 (18) 0 5 (13)
Gemcitabine  Caelyx  carboplatin 0 11 (100) 11 (28)
Response to 1st line, no. (%)
0 (no) 22 (79) 7 (64) 28 (72)
1 (yes) 6 (21) 4 (36) 10 (21)
Pemetrexed treatment, no. (%)
2nd line 25 (89) 11 36 (92)
3rd line 3 (11) 0 3 (8)
Caelyx, liposomal doxorubicin.
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Assessments During Treatment
Baseline and predosing assessment included complete
history and physical examination, complete blood cell count,
calculated creatinine clearance, liver enzymes, blood electro-
lytes, blood albumin, calcium, and glucose. Survival was
defined as the time from pemetrexed treatment start to the
time of death from any cause. Time to disease progression
was defined as the time from treatment start until documented
progression or death from any cause. For patients without
disease progression at the time of analysis, the date of last
follow-up was considered right-censored. Duration of tumor
response was defined as the time from the first objective
status of a response to the time of documented disease
progression or death from any cause. Computed tomography
was performed before every other treatment and every 2
months after completion of study therapy.
The new modified RECIST (Response Evaluation Cri-
teria in Solid Tumors) criteria for the assessment of response
in MPM were applied.7 Change in disease was assessed by
measuring the tumor thickness perpendicular to the chest wall
or mediastinum in up to three involved areas of pleural rind
at least 2 cm apart on computed tomography scan, at baseline,
TABLE 2. Toxicity (Common Toxicity Criteria Grading) with Pemetrexed in
39 Malignant Pleural Mesothelioma Patients Previously Treated with
Platinum-Based Chemotherapy
No. (%) of Patients
Pemetrexed
(n  28)
Pemetrexed  Carboplatin
(n  11)
Total
(n  39)
Nausea
NA 0 3 (27) 3 (8)
0 16 (57) 6 (55) 22 (56)
1 9 (32) 0 9 (23)
2 2 (7) 2 (18) 4 (10)
3 1 (4) 0 1 (3)
Leukocytes
NA 0 3 (27) 3 (8)
0 12 (43) 0 12 (31)
1 7 (25) 0 7 (18)
2 5 (18) 7 (64) 12 (31)
3 2 (7) 1 (9) 3 (8)
4 2 (7) 0 2 (5)
Thrombocytes
NA 0 3 (27) 3 (8)
0 20 (71) 0 20 (51)
1 6 (21) 2 (18) 8 (21)
2 0 4 (36) 4 (10)
3 1 (4) 2 (18) 3 (8)
4 1 (4) 0 1 (3)
Febrile leukopenia
NA 0 3 (27) 3 (8)
0 no 27 (96) 8 (73) 35 (92)
1 yes 1 (4) 0 1 (3)
Bleeding episodes
NA 0 3 (27) 3 (8)
0 no 28 (100) 8 (73) 36 (82)
1 yes 0 0 0
Dose reduction
NA 0 3 (27) 3 (8)
0 27 (96) 5 (46) 32 (82)
1 1 (4) 3 (27) 4 (10)
Retreatment postponed
NA 0 3 (27) 3 (8)
0 24 (86) 6 (55) 30 (77)
1 4 (14) 2 (18) 6 (15)
NA, not available.
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and every other cycle (at least one measurement was 1.5
cm). A reduction of at least 30% on two occasions 4 weeks apart
defined a partial response; an increase of 20% over the nadir
measurement was defined as progressive disease.7 A complete
response was defined as complete absence of all signs of disease
without any new lesions or disease-related symptoms.
RESULTS
Patients Characteristics
Thirty-nine patients were enrolled from March 2004
until March 2006.Twenty-eight Danish patients received
pemetrexed, three of these as third-line treatment and the
others as second-line treatment. Eleven Norwegian patients
received pemetrexed plus carboplatin as second-line treat-
ment (Table 1). Most patients were men (90%), had epithelial
subtype (85%), performance status of 0 to 1 (90%), and Inter-
national Mesothelioma Interest Group stages III to IV (77%).
Median age was 62 years (range, 30–77). Median lead times
from initial diagnosis to start of study therapy were 283 days
(range, 86–956) for pemetrexed and 389 days (range, 174–778)
for pemetrexed plus carboplatin. This difference of 3.4 months
in median is not statistically significant and may be due to
stochastic variation, but may also reflect difficulties in getting
resources for pemetrexed treatment to the Norwegian patients.
The previous chemotherapy regimens are shown in
Table 1. Eleven patients (28%) had experienced objective
tumor response to previous chemotherapy.
Toxicity
A total of 252 treatment courses were delivered, with a
median of six (range, 1–23). Common Toxicity Criteria grade
3 or 4 toxicity occurred only with respect to leukopenia (14%
with pemetrexed; 9% with pemetrexed plus carboplatin),
thrombocytopenia (7% and 18%, respectively), and nausea
(4% and 0%, respectively) (Table 2). There were no bleeding
episodes, but one death due to sepsis with pemetrexed. This
death occurred during the patient’s third treatment course
with both platelet and leukocyte count nadir of grade 4. The
patient was admitted in poor clinical condition with high
fever of 40.1°C and hypotension and died on the first day in
hospital. There were no positive bacteriologic findings. Other
less severe toxic effects of Common Toxicity Criteria grades 1
to 2 included tiredness (71% of patients), skin rash (32%), oral
mucositis (15%), constipation (11%), and neurotoxicity (4%).
Dose was reduced in 4% of cases treated with pem-
etrexed and in 27% treated with pemetrexed plus carboplatin,
and retreatment was postponed in 14% and 18%, respectively
(Table 2). Postponements were not longer than 2 weeks.
Response and Survival
Partial responses rates were 21% with pemetrexed and
18% with pemetrexed and carboplatin. A progression-free
survival curve is shown in Figure 1. Median times to pro-
gression were 147 days and 222 days, respectively, whereas
median survival times were 294 days and 258 days (Table 3).
An overall survival curve is shown in Figure 2. A total of 13
patients are alive, and the 1-year survival rate is 36% for both
pemetrexed and pemetrexed plus carboplatin (Table 3).
Partial responses occurred in two of 11 patients (18%)
who responded to first-line treatment and in six of 23 patients
without previous response (21%). One of three patients receiv-
ing pemetrexed as third-line treatment had partial response.
These three patients had received vinorelbine plus cisplatin as
first-line and gemcitabine plus liposomal doxorubicin plus car-
boplatin as second-line treatment. Two partial responses oc-
curred with pemetrexed in five patients with the biphasic type
and four of 22 patients with the epithelial subtype.
DISCUSSION
Platinum-based combination chemotherapy has been
more efficacious than single-agent cisplatin in phase III trials,
both with respect to the combination of pemetrexed and
cisplatinum6 and also raltitrexed plus cisplatinum.8 Both of
these randomized trials used antifolates and observed signif-
icantly prolonged survival with response rates and median
survivals for the combinations of 41% and 12.1 months (p 
0.02) and 23.6% and 11.4 months (p  0.048), respectively.6,8
Based on these data, the combination of cisplatin with
pemetrexed or raltitrexed can reasonably be offered as a
first-line option in MPM. A number of other combination
regimens using platinum compounds together with, for ex-
ample, doxorubicin,9 liposomal doxorubicin,10 epirubicin,11
gemcitabine,12,13 and vinorelbine,14 have also yielded prom-
ising results, although in nonrandomized studies. No random-
ized trials have as yet compared the efficacy of different
combination chemotherapy regimens.15 A number of patients
treated with one of these regimens as first-line chemotherapy
have a good performance status when progression of the
disease is documented and inquire about second-line treat-
ment. Because of the positive results obtained with antifolates
as first-line treatment, these agents might be considered for
second-line if the patients have not previously been exposed
to this group of cytostatics. The current study indicates that
FIGURE 1. Progression-free survival for 39 patients with
malignant pleural mesothelioma receiving second- or third-
line treatment with pemetrexed alone (n  28) or pem-
etrexed plus carboplatin (n  11). Median progression-free
survival was 6.1 months.
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such a strategy is justified and that a noteworthy rate of
durable responses may be obtained.
Responses to pemetrexed were observed in patients
previously treated with gemcitabine, liposomal doxorubicin,
and vinorelbine. This indicates that there is no cross-resis-
tance between these agents and pemetrexed. Such knowledge
may be of potential use in the reverse situation, i.e., in
patients who have received pemetrexed as part of the first-line
treatment and who are considered for subsequent chemother-
apy. The apparent absence of cross-resistance may further
support the finding by Manegold et al.16 that second-line
chemotherapy after progression to pemetrexed plus cisplatin
or cisplatin alone may possibly increase survival as patients
who received subsequent second-line treatment survived
longer than those who did not. However, there may be other
explanations for the finding of a prolonged survival such as
imbalances of known or unknown prognostic variables,16 and
firm conclusions regarding a survival effect by second-line
treatment cannot be drawn.
Although first-line chemotherapy in MPM is current
standard of care,17 fewer data are available concerning the
role of second-line treatment or beyond. A literature review
identified 16 trials on chemotherapy in previously treated
MPM patients.18 Partial response rates to a variety of agents
were low, being 5% to 10% in many of these studies. A recent
study evaluated a combination of raltitrexed plus oxaliplatin
as second-line treatment.19 Even though this combination is
active in previously untreated patients, with response rates of
30% to 35%,20 there were no responses among 14 patients
pretreated with one of six chemotherapy regimens including
doxorubicin, gemcitabine, pemetrexed, and methotrexate.19
FIGURE 2. Overall survival for 39 patients with malignant
pleural mesothelioma receiving second- or third-line treat-
ment with pemetrexed alone (n  28) or pemetrexed plus
carboplatin (n  11). Median overall survival was 9.7
months.
TABLE 3. Treatment Results with Pemetrexed in Malignant Pleural Mesothelioma
Patients Previously Treated with Platinum-Based Combination Chemotherapy
Response
Pemetrexed
(n  28)
Pemetrexed  Carboplatin
(n  11)
Total
(n  39)
Partial, no. (%) 6 (21) 2 (18) 8 (21)
95% CI 8.3–40.9 2.3–51.8 9.3–36.5
No. of treatment courses
1 2 0 2
2 3 1 4
3 1 2 3
4 2 1 3
5 2 1 3
6 8 1 9
7 0 1 1
8 6 0 6
9 4 2 6
20 — 1 1
23 — 1 1
Median (range) 6 (1–9) 6 (2–23) 6 (1–23)
Time to progression, d
Median (range) 147 (30–644) 222 (50–898) 183 (30–898)
Survival, d
Median (range) 294 (30–697) 258 (71–898) 291 (30–898)
Survival status
Dead 18 8 26 (67%)
Alive 10 3 13 (33%)
1-yr survival 10 (36%) 4 (36%) 14 (36%)
CI, confidence interval.
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This is contrast with the current study in which two of five
patients who initially received gemcitabine plus carboplatin
experienced partial responses to subsequent pemetrexed. Also
two of 11 patients who initially received gemcitabine and car-
boplatin together with liposomal doxorubicin responded to sub-
sequent pemetrexed plus carboplatin. This suggests a role for
pemetrexed in second-line treatment of MPM.
The impact of histology on responsiveness to chemother-
apy is well established, with the epithelial subtype being the
most responsive to chemotherapy and having the best progno-
sis.21 It is thus of interest that responses to second-line pem-
etrexed did occur also among patients having biphasic histology.
A recent phase II study of pemetrexed plus carboplatin
in 19 chemotherapy-naive patients revealed a response rate of
18.6% and a median time to progression of 6.5 months.22
These figures are similar to the results with an identical
regimen used as second-line treatment in 11 patients in the
current study (18.2% response rate and a median time to
progression of 222 days [7.4 months]). It appears also similar
to the results with pemetrexed alone in second-line treatment
(21.4% response rate and a median time to progression of 147
days [4.9 months]) although the patients receiving the com-
bination treatment had a trend toward more favorable prog-
nostic factors than patients treated with pemetrexed alone,
albeit not statistically significant. Increased myelotoxicity
due to carboplatin may contribute to the lack of increased
activity. It might thus be questioned whether carboplatin
contributes to the activity of the combination in the second-
line treatment setting if patients had been pretreated with
carboplatin. This study cannot answer whether carboplatin is
less active than cisplatin in MPM. The difference of 3.4
months in median lead time to pemetrexed treatment between
the Danish and Norwegian patients is not statistically signif-
icant and may be due to stochastic variation, but may also
reflect difficulties in getting resources for pemetrexed treat-
ment to the Norwegian patients.
Another analysis of pemetrexed as second-line treat-
ment in MPM based on data from an expanded access
program was recently published.23 A total of 187 pretreated
patients received either pemetrexed alone (91 patients) or
pemetrexed plus cisplatin (96 patients). The response rates
were 32% for the combination of pemetrexed and cisplatin
but only 5.5% for pemetrexed alone. The median survivals
were 7.6 months for the combination and 4.1 months for the
single agent. The Danish/Norwegian series differs in that the
pemetrexed response rate was higher and the pemetrexed plus
carboplatin response rate and median survival do not seem better
than those with pemetrexed alone. However, given the nonran-
domized nature of both data sets, it is possible that prognostic
factor imbalances between the two groups in this study and that
of Janne et al.23 would account for the differences.
The influence of second-line chemotherapy on the clinical
course of MPM remains unclear even though a reduction in
tumor burden seems obtainable in some patients based on data
from this and others studies. Whether this leads to an impact on
survival and quality of life is as yet unproven and should be
addressed in further trials. Preferably, a randomized trial of
pemetrexed versus placebo should be conducted in this setting.
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